Cargando…
A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma
Asthma is a chronic respiratory condition that is characterized by reversible airflow obstruction. Interleukin-5 (IL-5) is involved in the pathophysiology of the disease and drugs targeting IL-5 have been studied for years as a possible treatment option for severe asthma. In this review, the authors...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223665/ https://www.ncbi.nlm.nih.gov/pubmed/30416896 http://dx.doi.org/10.7759/cureus.3216 |
_version_ | 1783369439135137792 |
---|---|
author | Agumadu, Vivian C Ramphul, Kamleshun Mejias, Stephanie G Sonaye, Ruhi Sombans, Shaheen Lohana, Petras |
author_facet | Agumadu, Vivian C Ramphul, Kamleshun Mejias, Stephanie G Sonaye, Ruhi Sombans, Shaheen Lohana, Petras |
author_sort | Agumadu, Vivian C |
collection | PubMed |
description | Asthma is a chronic respiratory condition that is characterized by reversible airflow obstruction. Interleukin-5 (IL-5) is involved in the pathophysiology of the disease and drugs targeting IL-5 have been studied for years as a possible treatment option for severe asthma. In this review, the authors searched PubMed for major drug therapies and clinical trials against IL-5. A total of 29 articles met the criteria for selection and were shortlisted; of these, 10 papers were on benralizumab, 14 on mepolizumab, and five on reslizumab. The three drugs proved to be safe and efficacious for patients with severe asthma, leading to decreased rates of asthma exacerbations, lowered levels of eosinophils, and improved pulmonary functions in various studies. Patients also reported an improvement in the quality of life. The side effects of these three drugs were mild and no deaths directly linked to the drug were reported. However, longer duration studies are required to draw firm and strong conclusions on the safety of these therapeutic agents. |
format | Online Article Text |
id | pubmed-6223665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-62236652018-11-09 A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma Agumadu, Vivian C Ramphul, Kamleshun Mejias, Stephanie G Sonaye, Ruhi Sombans, Shaheen Lohana, Petras Cureus Internal Medicine Asthma is a chronic respiratory condition that is characterized by reversible airflow obstruction. Interleukin-5 (IL-5) is involved in the pathophysiology of the disease and drugs targeting IL-5 have been studied for years as a possible treatment option for severe asthma. In this review, the authors searched PubMed for major drug therapies and clinical trials against IL-5. A total of 29 articles met the criteria for selection and were shortlisted; of these, 10 papers were on benralizumab, 14 on mepolizumab, and five on reslizumab. The three drugs proved to be safe and efficacious for patients with severe asthma, leading to decreased rates of asthma exacerbations, lowered levels of eosinophils, and improved pulmonary functions in various studies. Patients also reported an improvement in the quality of life. The side effects of these three drugs were mild and no deaths directly linked to the drug were reported. However, longer duration studies are required to draw firm and strong conclusions on the safety of these therapeutic agents. Cureus 2018-08-27 /pmc/articles/PMC6223665/ /pubmed/30416896 http://dx.doi.org/10.7759/cureus.3216 Text en Copyright © 2018, Agumadu et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Agumadu, Vivian C Ramphul, Kamleshun Mejias, Stephanie G Sonaye, Ruhi Sombans, Shaheen Lohana, Petras A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma |
title | A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma |
title_full | A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma |
title_fullStr | A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma |
title_full_unstemmed | A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma |
title_short | A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma |
title_sort | review of three new anti-interleukin-5 monoclonal antibody therapies for severe asthma |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223665/ https://www.ncbi.nlm.nih.gov/pubmed/30416896 http://dx.doi.org/10.7759/cureus.3216 |
work_keys_str_mv | AT agumaduvivianc areviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma AT ramphulkamleshun areviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma AT mejiasstephanieg areviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma AT sonayeruhi areviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma AT sombansshaheen areviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma AT lohanapetras areviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma AT agumaduvivianc reviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma AT ramphulkamleshun reviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma AT mejiasstephanieg reviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma AT sonayeruhi reviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma AT sombansshaheen reviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma AT lohanapetras reviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma |